Advertisement

SCN1A and SCN2A polymorphisms are associated with response to valproic acid in Chinese epilepsy patients

  • Lihong Shi
  • Miaomiao Zhu
  • Huilan Li
  • Zhipeng Wen
  • Xiaoping Chen
  • Jia Luo
  • Cong Lin
  • Zanling ZhangEmail author
Pharmacogenetics
  • 45 Downloads

Abstract

Purpose

There is a large inter-individual variation in the efficacy of valproic acid (VPA) against epilepsy. The genetic polymorphism influence of sodium channels on VPA response remains a matter of debate. The aim of the study was to explore the effect of SCN1A and SCN2A gene polymorphisms on VPA response in the treatment of epilepsy among Chinese patients.

Methods

A total of 354 epileptic patients with VPA treatment were genotyped for five single nucleotide polymorphisms (SNP), including SCN1A rs10188577 T>C, rs2298771 T>C, rs3812718 G>A, and SCN2A rs2304016 A>G, rs17183814 G>A. A binary logistic regression analysis was performed to evaluate the association of genotype with VPA antiepileptic effects, adjusting the influence of confounding factors.

Results

Genotype distributions of all selected SNPs were consistent with the Hardy–Weinberg equilibrium in epilepsy patients. SCN1A rs3812718 and SCN2A rs2304016 were found to be significantly associated with VPA response, both in monotherapy and in VPA-based polytherapy. Patients with the rs3812718 A allele were more frequently seen in the VPA-responsive group (P < 0.05), and the rs2304016 G allele was related to an increased risk of resistance to VPA therapy (P < 0.05).

Conclusions

Our study revealed that SCN1A rs3812718 and SCN2A rs2304016 polymorphisms might be markers of VPA response in Chinese epilepsy patients.

Trial registration

ChiCTR-1800016477

Keywords

Epilepsy Valproic acid SCN1A SCN2A Antiepileptic efficacy 

Notes

Acknowledgments

We thank all patients and their family members who contributed to this work. We thank Professor Shusen Sun from College of Pharmacy and Health Sciences at Western New England University, USA, for his valuable advice.

Contributions of authors

Zanling Zhang designed the study. Lihong Shi performed the data analysis and wrote the manuscript. Miaomiao Zhu, Huilan Li, and Zhipeng Wen recruited patients and conducted patients’ follow-up. Jia Luo and Cong Lin extracted the DNA. Xiaoping Chen reviewed the manuscript and critically revised the intellectual content of the manuscript.

Funding information

This work was supported by a grant from the Natural Science Foundation of Hunan Province (no. 2017JJ2398).

Compliance with ethical standards

All procedures performed in studies involving human participants were in accordance with the ethical standards of Xiangya Hospital Central South University Medical Ethics Committee, and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

228_2019_2633_MOESM1_ESM.docx (19 kb)
ESM 1 (DOCX 19 kb)

References

  1. 1.
    Moshé SL, Perucca E, Ryvlin P, Tomson T (2015) Epilepsy: new advances. Lancet 385:884–898Google Scholar
  2. 2.
    Verrotti A, Mazzocchetti C (2016) Epilepsy: beyond seizures-the importance of comorbidities in epilepsy. Nat Rev Neurol 12:559–560Google Scholar
  3. 3.
    Brodie MJ, Besag F, Ettinger AB, Mula M, Gobbi G, Comai S, Aldenkamp AP, Steinhoff BJ (2016) Epilepsy, antiepileptic drugs, and aggression: an evidence-based review. Pharmacol Rev 68:563–602Google Scholar
  4. 4.
    Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, Moshé SL, Perucca E, Wiebe S, French J (2010) Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 51:1069–1077Google Scholar
  5. 5.
    Zhu MM, Li HL, Shi LH, Chen XP, Luo J, Zhang ZL (2017) The pharmacogenomics of valproic acid. J Hum Genet 62:1009–1014Google Scholar
  6. 6.
    Chateauvieux S, Morceau F, Dicato M, Diederich M (2010) Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol 2010Google Scholar
  7. 7.
    Marson AG, Al-Kharusi AM, Alwaidh M et al (2007) The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 369:1016–1026Google Scholar
  8. 8.
    Oyrer J, Maljevic S, Scheffer IE, Berkovic SF, Petrou S, Reid CA (2018) Ion channels in genetic epilepsy: from genes and mechanisms to disease-targeted therapies. Pharmacol Rev 70:142–173Google Scholar
  9. 9.
    Catterall WA, Kalume F, Oakley JC (2010) NaV1.1 channels and epilepsy. J Physiol 588:1849–1859Google Scholar
  10. 10.
    Szulczyk B, Nurowska E (2017) Valproic acid inhibits TTX-resistant sodium currents in prefrontal cortex pyramidal neurons. Biochem Biophys Res Commun 491:291–295Google Scholar
  11. 11.
    Löscher W (1999) Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Prog Neurobiol 58:31–59Google Scholar
  12. 12.
    Johannessen CU (2000) Mechanisms of action of valproate: a commentatory. Neurochem Int 37:103–110Google Scholar
  13. 13.
    Zuliani V, Fantini M, Rivara M (2012) Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders. Curr Top Med Chem 12:962–970Google Scholar
  14. 14.
    Catterall WA (2014) Sodium channels, inherited epilepsy, and antiepileptic drugs. Annu Rev Pharmacol Toxicol 54:317–338Google Scholar
  15. 15.
    Yu FH, Mantegazza M, Westenbroek RE, Robbins CA, Kalume F, Burton KA, Spain WJ, McKnight GS, Scheuer T, Catterall WA (2006) Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy. Nat Neurosci 9:1142–1149Google Scholar
  16. 16.
    Haerian BS, Baum L, Tan HJ, Kwan P, Raymond AA, Saruwatari J, Nakagawa K, Mohamed Z (2012) SCN1AIVS5N+5 polymorphism and response to sodium valproate: a multicenter study. Pharmacogenomics 13:1477–1485Google Scholar
  17. 17.
    Yip TS, O'Doherty C, Tan NC, Dibbens LM, Suppiah V (2014) SCN1A variations and response to multiple antiepileptic drugs. Pharmacogenomics J 14:385–389Google Scholar
  18. 18.
    Li X, Zhang J, Wu X, Yan H, Zhang Y, He RH, Tang YJ, He YJ, Tan D, Mao XY, Yin JY, Liu ZQ, Zhou HH, Liu J (2016) Polymorphisms of ABAT, SCN2A and ALDH5A1 may affect valproic acid responses in the treatment of epilepsy in Chinese. Pharmacogenomics 17:2007–2014Google Scholar
  19. 19.
    Duan SH, Ma JL, Yang XL, Guo YF (2017) Simultaneous multigene mutation screening using SNPscan in patients from ethnic minorities with nonsyndromic hearingimpairment in Northwest China. Mol Med Rep 16:6722–6728Google Scholar
  20. 20.
    Ma CL, Wu XY, Jiao Z, Hong Z, Wu ZY, Zhong MK (2014) Association of SCN1A, SCN2A and ABCC2 gene polymorphisms with the response to antiepileptic drugs in Chinese Han patients with epilepsy. Pharmacogenomics 15:1323–1336Google Scholar
  21. 21.
    Zhou BT, Zhou QH, Yin JY, Li GL, Qu J, Xu XJ, Liu D, Zhou HH, Liu ZQ (2012) Effects of SCN1A and GABA receptor genetic polymorphisms on carbamazepine tolerability and efficacy in Chinese patients with partial seizures: 2-year longitudinal clinical follow-up. CNS Neurosci Ther 18:566–572Google Scholar
  22. 22.
    Zhou BT, Zhou QH, Yin JY, Li GL, Xu XJ, Qu J, Liu D, Zhou HH, Liu ZQ (2012) Comprehensive analysis of the association of SCN1A gene polymorphisms with the retention rate of carbamazepine following monotherapy for new-onset focal seizures in the Chinese Han population. Clin Exp Pharmacol Physiol 39:379–384Google Scholar
  23. 23.
    Manna I, Gambardella A, Bianchi A, Striano P, Tozzi R, Aguglia U, Beccaria F, Benna P, Campostrini R, Canevini MP, Condino F, Durisotti C, Elia M, Giallonardo AT, Iudice A, Labate A, la Neve A, Michelucci R, Muscas GC, Paravidino R, Zaccara G, Zucca C, Zara F, Perucca E (2011) A functional polymorphism in the SCN1A gene does not influence antiepileptic drug responsiveness in Italian patients with focal epilepsy. Epilepsia 52:e40–e44Google Scholar
  24. 24.
    Zhou L, Cao Y, Long H, Long L, Xu L, Liu Z, Zhang Y, Xiao B (2015) ABCB1, ABCC2, SCN1A, SCN2A, GABRA1 gene polymorphisms and drug resistant epilepsy in the Chinese Han population. Pharmazie 70:416–420Google Scholar
  25. 25.
    Sánchez MB, Herranz JL, Leno C, Arteaga R, Oterino A, Valdizán EM, Nicolás JM, Adín J, Armijo JA (2010) Genetic factors associated with drug-resistance of epilepsy: relevance of stratification by patient age and aetiology of epilepsy. Seizure 19:93–101Google Scholar
  26. 26.
    Yun W, Zhang F, Hu C, Luo X, Xue P, Wang J, Ge Y, Meng H, Guo Y (2013) Effects of EPHX1, SCN1A and CYP3A4 genetic polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy. Epilepsy Res 107:231–237Google Scholar
  27. 27.
    Haerian BS, Baum L, Kwan P, Tan HJ, Raymond AA, Mohamed Z (2013) SCN1A, SCN2A and SCN3A gene polymorphisms and responsiveness to antiepileptic drugs: a multicenter cohort study and meta-analysis. Pharmacogenomics 14:1153–1166Google Scholar
  28. 28.
    Hung CC, Chang WL, Ho JL, Tai JJ, Hsieh TJ, Huang HC, Hsieh YW, Liou HH (2012) Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and SCN2A genes with carbamazepine therapy optimization. Pharmacogenomics 13:159–169Google Scholar
  29. 29.
    Tate SK, Depondt C, Sisodiya SM, Cavalleri GL, Schorge S, Soranzo N, Thom M, Sen A, Shorvon SD, Sander JW, Wood NW, Goldstein DB (2005) Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc Natl Acad Sci U S A 102:5507–5512Google Scholar
  30. 30.
    Tate SK, Singh R, Hung CC, Tai JJ, Depondt C, Cavalleri GL, Sisodiya SM, Goldstein DB, Liou HH (2006) A common polymorphism in the SCN1A gene associates with phenytoin serum levels at maintenance dose. Pharmacogenet Genomics 16:721–726Google Scholar
  31. 31.
    Eliasson E, Lindh JD, Malmström RE, Beck O, Dahl ML (2013) Therapeutic drug monitoring for tomorrow. Eur J Clin Pharmacol 69(Suppl 1):25–32Google Scholar
  32. 32.
    Copley RR (2004) Evolutionary convergence of alternative splicing in ion channels. Trends Genet 20:171–176Google Scholar
  33. 33.
    Heinzen EL, Yoon W, Tate SK, Sen A, Wood NW, Sisodiya SM, Goldstein DB (2007) Nova2 interacts with a cis-acting polymorphism to influence the proportions of drug-responsive splice variants of SCN1A. Am J Hum Genet 80:876–883Google Scholar
  34. 34.
    Fletcher EV, Kullmann DM, Schorge S (2011) Alternative splicing modulates inactivation of type 1 voltage-gated sodium channels by toggling an amino acid in the first S3-S4 linker. J Biol Chem 286:36700–36708Google Scholar
  35. 35.
    Anderson LL, Hawkins NA, Thompson CH, Kearney JA, George AL Jr (2017) Unexpected efficacy of a novel sodium channel modulator in Dravet syndrome. Sci Rep 7:1682Google Scholar
  36. 36.
    Brunklaus A, Ellis R, Reavey E, Forbes GH, Zuberi SM (2012) Prognostic, clinical and demographic features in SCN1A mutation-positive Dravet syndrome. Brain 135:2329–2336Google Scholar
  37. 37.
    Younus I, Reddy DS (2017) Epigenetic interventions for epileptogenesis: a new frontier for curing epilepsy. Pharmacol Ther 177:108–122Google Scholar
  38. 38.
    Kumari R, Lakhan R, Kumar S, Garg RK, Misra UK, Kalita J, Mittal B (2013) SCN1AIVS5-91G>A polymorphism is associated with susceptibility to epilepsy but not with drug responsiveness. Biochimie 95:1350–1353Google Scholar
  39. 39.
    Tang L, Lu X, Tao Y, Zheng J, Zhao P, Li K, Li L (2014) SCN1A rs3812718 polymorphism and susceptibility to epilepsy with febrile seizures: a meta-analysis. Gene 533:26–31Google Scholar
  40. 40.
    Kwan P, Poon WS, Ng HK, Kang DE, Wong V, Ng PW, Lui CH, Sin NC, Wong KS, Baum L (2008) Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: correlation among phenotype, genotype, and mRNA expression. Pharmacogenet Genomics 18:989–998Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Pharmacy, Xiangya HospitalCentral South UniversityChangshaChina
  2. 2.Institute of Hospital PharmacyCentral South UniversityChangshaChina
  3. 3.Department of Clinical Pharmacology, Xiangya HospitalCentral South UniversityChangshaChina
  4. 4.Institute of Clinical PharmacologyCentral South UniversityChangshaChina

Personalised recommendations